Form 4 Filing for Keith J. Lane

Keith J. Lane, EVP of Clinical and Regulatory at Kiora Pharmaceuticals Inc., was granted a stock option to purchase 55,000 shares of Common Stock on September 17, 2026. The option has an exercise price of $2.67 and an expiration date of September 17, 2036. The option vests in three installments: one-third on September 17, 2027, and the remaining balance vests monthly over the subsequent two years, contingent upon continuous service. Following this transaction, Lane holds 55,000 shares of Common Stock.